- Defence Therapeutics Inc.’s (DTC) recent pre-clinical study showed hopeful results for its AccuTOX formulation on animals with pre-established lung cancer
- When AccuTOX was administered as a combination therapy with an immune-checkpoint inhibitor, anti-PD1, it reduced the level of lung nodules by 50 per cent
- This result was achieved with six administrated nasal passageway doses over two weeks
- The company is preparing for a meeting to get approval for a phase one trial against solid tumours in 2023
- Defence Therapeutics Inc. (DTC) is up 2.70 per cent and at $2.28 per share as of 10:08 a.m. EST
Defence Therapeutics’ (DTC) recently completed pre-clinical study showed hopeful results for its AccuTOX formulations on animals with pre-established lung cancer.
The study showed that when AccuTOX was administered as a combination therapy with an immune-checkpoint inhibitor, anti-PD1, it reduced the level of lung nodules by 50 per cent.
This result was achieved with six administrated nasal passageway doses over two weeks with the AccuTOX anti-PD1 combination plan. It was well tolerated at five to six times lower than the injectable dose.
Sebastien Plouffe, President and CEO of Defence, commented,
“The compound has not only shown a great potential in treating solid tumours, but we now have data demonstrating that it can be further adapted and delivered via the intranasal route to treat lungs with metastatic tumours… this will open up a completely new horizon for AccuTOX as an anti-cancer treatment.”
The AccuTOX program is one of Defence’s most advanced immune-oncology programs, which was originally designed to display enhanced anti-tumour properties compared to its original Accum molecule. The company is currently preparing for its U.S. Food and Drug Administration meeting regarding a phase one trial against solid tumours in 2023.
Defence Therapeutics Inc. (DTC) is up 2.70 per cent and is trading at $2.28 per share as of 10:08 a.m. EST.
